-
'We have to be stronger': De Zerbi demands Spurs improve as relegation fears mount
-
Man City will not risk Rodri in FA Cup semi-final: Guardiola
-
Macron leaves future open as political curtain nears
-
Germany launches spying probe into Signal attacks targeting MPs
-
Arsenal haven't given up on title despite blowing lead: Arteta
-
Injured Spain star Yamal will come back stronger at World Cup: Flick
-
Oil prices fall on hopes of fresh Iran peace talks
-
Chelsea can still save season despite slump: McFarlane
-
Echoing Diana, Prince Harry visits Ukraine's deminers
-
Chelsea's Estevao out for season, World Cup in doubt
-
PSG's Luis Enrique 'couldn't care less' about World Cup
-
Ryanair says to cut Berlin flights, blaming taxes
-
From sun to subsoil, how countries are moving away from fossil fuels
-
London's Jewish community on edge amid attacks
-
Ranieri's Roma role ends after spat with coach Gasperini: club
-
Warming El Nino set to return in mid-2026: UN
-
Porsche exits sports car maker Bugatti Rimac
-
Bill legalising assisted dying in England and Wales set to fail
-
Chinese EVs, flying cars take centre stage at world's biggest auto show
-
Macron says still sees France, Germany developing European fighter jet
-
Al Ahli star Mahrez warns team-mates not to take Japanese rivals for granted
-
Greece expands sunbed-free beach list for 2026
-
Rugby legend McCaw hails 'spectacular' NZ stadium built after deadly quake
-
Mideast war drives up condom, rubber glove prices: manufacturers
-
Gulf states in limbo as US-Iran crisis drags on
-
Liverpool's Slot warns 'margins are small' in Champions League push
-
Musk says Tesla has started 'robotaxi' production
-
Suspected Nazi-looted Stradivarius reappears in France, says expert
-
Glacier block delays route-setting on Everest
-
Appeal board says homophobia 'commonplace' in Aussie Rules
-
Hot pants: Tokyo government workers swap suits for shorts
-
Chinese EV makers take centre stage at world's biggest auto show
-
Concern stirs Lula camp as election bid loses momentum
-
China's top AI players
-
Five things to know about Chinese AI startup DeepSeek
-
Possible Trump rescue of Spirit Airlines spurs debate
-
Wild Balkan berries keep gin taste steady as climate shifts
-
Mass MS-13 trial held at El Salvador mega-jail
-
Barcelona must live without teen star Yamal for title run-in
-
Hearts lead Old Firm as Scottish title race heads for tense finale
-
India criticizes 'poor taste' Trump post against immigrants
-
China's DeepSeek says releases long-awaited new AI model
-
Hawks fend off Knicks, Raptors pull away from Cavs to cut deficit
-
Wildfires spread towards northern Japan town
-
Israel, Lebanon extend ceasefire as Iran peace talks stall
-
'Clearly me': AI drama accused of stealing faces
-
Soviet architecture vanishes as Central Asia drifts from Moscow
-
Oil extends gains, stocks sink as peace talk hopes fade
-
'Raw and honest': India climbers face obstacles in race to the top
-
Cowgirls of Philippine rodeo tackle steers, stereotypes
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their families by developing truly transformational and highly disease-specific immunotherapies that are potentially curative. Barinthus Bio's pipeline for I&I indications is enabled by our proprietary and highly differentiated platform for promoting immune tolerance, SNAP-TI, that is designed to guide a patient's T cells to a specific location to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease and is currently in a Phase 1 clinical trial. Barinthus Bio's differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with autoimmune and inflammatory diseases. For more information, visit www.barinthusbio.com.
Event: Q2 Investor Summit
Presentation Time: June 10, 11:00 - 11:30 AM ET
Location: WEBCAST LINK
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who have a near-term catalyst and are undervalued.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
AccessNewswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESSWIRE
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Investor Summit Group
View the original press release on ACCESS Newswire
P.Stevenson--AMWN